OSD
There is a growing interest among drug developers and manufacturers in the use of modified release (MR) oral dosage forms. MR formulations offer formulation scientists and patients many advantages, such as improved efficacy, increased convenience and optimised performance. Furthermore, the adoption of MR pellet technology simplifies the modification process for manufacturers.
Despite the various benefits and progress pellet technology provides in terms of performance, there are still challenges in MR development with alcohol resistance properties.
Philippe Gorria, senior director – pharmaceutical development, and Jérôme Revel, senior development engineer, at Recipharm have authored an article for Pharmaceutical Technology discussing what is driving drug developers and manufacturers’ interest in the use of MR oral dosage forms. They explore the benefits of pellet technology and the challenges in MR development.